Herein, we utilized bioinformatics analysis tools to explore the expression and multilevel clinical value of ENOs in BLCA, and identified ENO1 as a promising immune-related target, providing a novel strategy for the diagnosis and clinical treatment of BLCA. The gene discussed is ENO1; the disease is bladder transitional cell carcinoma.